Madrigal Pharmaceuticals (MDGL) Other financing activities (2018 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Other financing activities of $3.1 million for Q2 2026, up 78.75% year-over-year from $1.7 million in Q2 2025, and up 33.62% quarter-over-quarter from $2.3 million in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Other financing activities (2018 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Other financing activities for 4 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 14.96 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.11 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 8.64 Mn |
| Sep 30, 2021 | 7,000.00 |
| Sep 30, 2018 | 451,000.00 |